Adjunct Treatment With Cariprazine for Adults With Attention-deficit/Hyperactivity Disorder
(ADHD Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing whether adding a small dose of cariprazine, a medication that affects brain chemicals, can help adults with ADHD who don't respond well to standard treatments. The goal is to see if this combination can better manage their symptoms. Cariprazine works by balancing chemicals in the brain that are important for attention and behavior.
Will I have to stop taking my current medications?
You can continue taking your current long-acting psychostimulant and any other stable psychotropic medications, except antipsychotics. If you are using recreational drugs, including cannabis, you must stop at least 2 weeks before joining the study.
What safety data exists for Cariprazine?
How does the drug cariprazine differ from other treatments for schizophrenia and bipolar disorder?
Cariprazine is unique because it is a third-generation antipsychotic that acts as a partial agonist (activator) at dopamine D2 and D3 receptors, with a preference for D3, and also affects serotonin receptors. This mechanism may help address both positive and negative symptoms of schizophrenia, which are often challenging to treat, and it has shown efficacy in improving symptoms with generally mild to moderate side effects.678910
Research Team
Martin A Katzman, MD
Principal Investigator
Clinic Director
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive adjunct treatment with cariprazine alongside their stable dose of psychostimulants
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cariprazine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dr. Martin A. Katzman
Lead Sponsor